fibrogen
presents
abstract
results
associations
hemoglobin
levels
cardiovascular
outcomes
patients
anemia
chronic
kidney
disease
ckd
ckd
patients
major
adverse
cardiovascular
event
mace
incidence
rates
lowest
patients
achieved
hemoglobin
levels
g
dl
two
analyses
pooled
data
roxadustat
global
phase
development
program
presented
american
society
nephrology
kidney
week
reimagined
san
francisco
globe
newswire
fibrogen
nasdaq
fgen
today
announced
results
two
analyses
pooled
data
roxadustat
global
phase
development
program
examining
associations
achieved
hemoglobin
hb
levels
cardiovascular
outcomes
ndd
dd
patients
anemia
chronic
kidney
disease
ckd
results
analyses
three
trials
ndd
patients
three
trials
dd
patients
respectively
showed
major
adverse
cardiovascular
events
mace
mortality
myocardial
infarction
stroke
mace
plus
heart
failure
unstable
angina
requiring
hospitalization
rates
highest
hb
less
g
dl
decreased
hb
increased
lowest
hb
levels
greater
equal
g
dl
data
abstracts
accepted
abstracts
featured
clinical
trials
posters
session
american
society
nephrology
asn
kidney
week
reimagined
october
evidence
roxadustat
effective
increasing
maintaining
hemoglobin
levels
patients
anemia
chronic
kidney
disease
shown
across
roxadustat
clinical
program
new
analyses
showed
patients
treated
roxadustat
rates
cardiovascular
events
lowest
patients
hemoglobin
levels
greater
g
dl
said
robert
provenzano
md
associate
professor
medicine
wayne
state
university
detroit
michigan
primary
investigator
roxadustat
global
phase
program
additional
safety
results
coupled
roxadustat
efficacy
profile
oral
formulation
support
potential
roxadustat
become
safe
effective
treatment
option
anemia
chronic
kidney
disease
area
seen
little
therapeutic
progress
last
analyses
incidence
rates
adjudicated
mace
evaluated
based
hb
level
immediately
event
ndd
ckd
population
mace
rates
highest
hb
less
g
dl
decreased
hb
increased
lowest
achieved
hb
levels
greater
equal
g
dl
parameter
maximum
hemoglobin
g
dl
g
dl
g
dl
g
dl
g
dl
g
dl
outcome
time
point
event
rate
pey
ci
mace
immediately
event
immediately
event
pey
pey
years
similarly
dd
ckd
population
mace
rates
highest
hb
less
g
dl
decreased
hb
increased
lowest
achieved
hb
levels
greater
equal
g
dl
parameter
maximum
hemoglobin
g
dl
g
dl
g
dl
g
dl
g
dl
g
dl
outcome
time
point
event
rate
pey
ci
mace
immediately
event
immediately
event
pey
pey
years
anemia
typically
develops
patients
chronic
kidney
disease
worsens
disease
progresses
decreasing
oxygenation
resulting
increased
risk
cardiovascular
complications
death
said
peony
yu
chief
medical
officer
fibrogen
delighted
presenting
additional
results
demonstrate
potential
roxadustat
meaningful
treatment
option
chronic
kidney
disease
patients
anemia
ckd
chronic
kidney
disease
ckd
generally
progressive
disease
characterized
gradual
loss
kidney
function
may
eventually
lead
kidney
failure
end
stage
renal
disease
requiring
dialysis
kidney
transplant
ckd
estimated
occur
approximately
adults
worldwide
predicted
become
fifth
common
cause
premature
death
globally
anemia
serious
medical
condition
patients
insufficient
red
blood
cells
low
levels
hemoglobin
common
early
complication
ckd
affecting
approximately
ckd
patients
anemia
ckd
associated
increased
risk
hospitalization
cardiovascular
complications
death
also
cause
significant
fatigue
cognitive
dysfunction
reduced
quality
life
blood
transfusions
used
treating
severe
anemia
however
may
reduce
patient
opportunity
kidney
transplant
increase
risk
infection
complications
heart
failure
allergic
reactions
roxadustat
roxadustat
oral
small
molecule
inhibitor
promotes
erythropoiesis
increased
endogenous
production
erythropoietin
improved
iron
absorption
transport
mobilization
downregulation
hepcidin
helps
overcome
negative
impact
inflammation
hemoglobin
synthesis
red
blood
cell
production
roxadustat
approved
china
treatment
anemia
adult
patients
ckd
dialysis
dialysis
japan
roxadustat
approved
treatment
anemia
ckd
patients
dialysis
supplemental
nda
treatment
anemia
ckd
patients
dialysis
regulatory
review
roxadustat
nda
treatment
anemia
ckd
patients
dialysis
dialysis
review
food
drug
administration
prescription
drug
user
fee
act
date
december
marketing
authorization
application
roxadustat
treatment
anemia
ckd
patients
dialysis
dialysis
filed
partner
astellas
accepted
european
medicines
agency
review
may
roxadustat
also
clinical
development
anemia
associated
myelodysplastic
syndromes
mds
anemia
cia
astellas
fibrogen
collaborating
development
commercialization
roxadustat
treatment
anemia
territories
including
japan
europe
commonwealth
independent
states
middle
east
south
africa
astrazeneca
fibrogen
collaborating
development
commercialization
roxadustat
treatment
anemia
china
markets
americas
australia
new
zealand
well
southeast
asia
asn
kidney
week
reimagined
roxadustat
data
sponsored
presented
astellas
astrazeneca
fibrogen
fibrogen
fibrogen
biopharmaceutical
company
committed
discovering
developing
commercializing
pipeline
therapeutics
company
applies
pioneering
expertise
factor
hif
connective
tissue
growth
factor
ctgf
biology
advance
innovative
medicines
treatment
unmet
needs
company
currently
developing
commercializing
roxadustat
oral
small
molecule
inhibitor
hif
prolyl
hydroxylase
activity
anemia
associated
chronic
kidney
disease
ckd
roxadustat
also
clinical
development
anemia
associated
myelodysplastic
syndromes
mds
anemia
cia
pamrevlumab
human
monoclonal
antibody
clinical
development
treatment
idiopathic
pulmonary
fibrosis
ipf
locally
advanced
unresectable
pancreatic
cancer
lapc
duchenne
muscular
dystrophy
dmd
coronavirus
information
please
visit
statements
release
contains
statements
regarding
strategy
future
plans
prospects
including
statements
regarding
development
commercialization
company
product
candidates
potential
safety
efficacy
profile
product
candidates
clinical
programs
regulatory
events
partners
statements
include
limited
statements
plans
objectives
representations
contentions
historical
facts
typically
identified
use
terms
may
track
could
expect
plan
anticipate
believe
estimate
predict
potential
continue
similar
words
although
statements
expressed
differently
actual
results
may
differ
materially
indicated
statements
due
risks
uncertainties
related
continued
progress
timing
various
programs
including
enrollment
results
ongoing
potential
future
clinical
trials
matters
described
annual
report
form
fiscal
year
ended
december
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
sec
including
risk
factors
set
forth
therein
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
contacts
fibrogen
investors
michael
tung
investor
relations
mtung
media
jennifer
harrington
